Intermittent Neurogenic Claudication Treatment With APERIUS® (INCA)

January 26, 2016 updated by: Medtronic Spinal and Biologics

A Multicenter, Post Marketing Clinical Follow-up Study to Evaluate the Safety and Effectiveness of the Minimally Invasive Device APERIUS® in Degenerative Lumbar Spinal Stenosis With Symptomatic Neurogenic Intermittent Claudication

The primary purpose of the study is to measure the change in severity of symptoms and ability to function in every day activities in patients suffering from degenerative lumbar spinal stenosis after treatment with the Aperius® device.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The Intermittent Neurogenic Claudication Treatment with Aperius® (INCA) trial was designed as a multicenter single arm post-marketing study to evaluate the safety and effectiveness of the Aperius® in patients with degenerative lumbar stenosis with symptomatic neurogenic intermittent claudication.

One hundred fifty six patients with a history of Degenerative lumbar spinal stenosis (Lumbar level L1 to L5) at one or maximum 2 levels with symptoms of neurogenic intermittent claudication with or without back pain were included. All patients were followed for 12 months with visits at 48 hours, 7 days, 6 weeks, 6 and 12 months.

Primary effectiveness endpoint was assessed as the mean percentage change from baseline in Zurich Claudication Questionnaire for Symptom Severity at 6 weeks. Other effectiveness outcomes were percentage change in Zurich Claudication Questionnaire scores (ZCQ), Quality of laife Questionnaire scores (called EuroQuol 5D or EQ-5D), Visual Analogue Scale (VAS) pain scores (back, leg and buttock groin pain), pain medication and changes in walking distance from baseline to follow-up. Procedure and device related Serious Adverse Events were assessed throughout the complete 12 month follow-up period.

Study Type

Interventional

Enrollment (Actual)

162

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Antwerp, Belgium
        • Hospital Campus Middelheim
      • Bruges, Belgium
        • Academic Hospital Sint-Jan Brugge-Oostende AV
      • Brussels, Belgium
        • Park Léopold Hospital
      • Gosselies, Belgium
        • Notre Dame de Grace Hospital
      • La Louvière, Belgium
        • University Hospital Tivoli
      • Mons, Belgium
        • Hospital du Grand Hornu
  • Germany
      • Düsseldorf, Germany
        • Gemeinschaftspraxis Königsallee (Privat Clinic)
      • Erlangen, Germany
        • University Hospital Erlangen
      • Köln, Germany
        • Klinik und Poliklinik für Orthopädie (Hospital)
      • Schwandorf, Germany
        • Asklepios Hospital Lindenlohe
      • Schwarzach, Germany
        • Orthopädische Fachklinik Schwarzach (Hospital)
  • United Kingdom
      • Aberdeen, United Kingdom
        • Woodend Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • History of Degenerative Lumbar Spinal Stenosis (Lumbar spine level from L1 -L5), confirmed by Magnetic Resonance Imaging (MRI) at one or maximal two levels, with symptoms of intermittent neurogenic claudication.
  • Leg / Buttock / Groin pain, with or without back pain, relieved by flexion. If back pain is also present, it must be partially relieved when flexed.
  • Able to sit for 50 minutes without pain.
  • Able to walk a distance of 20 meters without pain.
  • Patient states availability for and willing to perform all follow -up examinations.
  • Patient signed informed consent form.
  • Adults (minimum 21 years of age).

Exclusion Criteria:

  • Previous lumbar surgery.
  • Unremitting pain (leg/buttock/groin/back) in any spinal position.
  • Axial back pain without leg/buttock/groin pain.
  • Significant lumbar instability at the affected level: spondylolisthesis greater than grade 1 on a scale from 1-4.
  • Objective motor deficit.
  • Significant peripheral neuropathy by nerve conduction velocity tests (peroneal and sural nerves) according to the investigator.
  • Cauda equina syndrome, defined as neural compression causing neurogenic bowel (rectal incontinence) or bladder dysfunction (retention or incontinence).
  • Spinal Stenosis with clinical symptoms at one or more levels outside the L1-L5 lumbar region.
  • Severe symptomatic Spinal Stenosis requiring immediate surgical decompression,according to the investigator or lumbar spinal stenosis at more than 2 levels.
  • Lumbar Spinal Stenosis, caused by tumors, metastasis or Paget's disease.
  • Vascular claudication and severe peripheral vascular disease. (Diminished dorsalis pedis or tibial pulses) that limits walking.
  • History of primary or secondary osteoporosis defined as a DXA scan (=dual energy x-ray absorptiometry) of the hip showing T-score (=the number of standard deviations above or below the mean for the patient's age, sex and ethnicity) of more than 2.5 standard deviation below the mean in the presence of one or more fragility fractures.
  • Active systemic infection or local infection at the level to treat.
  • Major Depression according to Diagnostic and Statistical Manual of Mental Disorders (DSM) IV criteria.
  • Dementia and/or inability to give informed consent.
  • Unable to complete the study.
  • Pregnancy and breastfeeding.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
OTHER: Aperius Treatment Arm
Single Arm
Device: Aperius® Percutaneous Interspinous Spacer
Implantation of the Aperius® device
Other Names:
  • Aperius®

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean Percentage Change in Symptom Severity at 6 Weeks Compared to Baseline, Using the Patient Completed Zurich Claudication Questionnaire for Symptom Severity
Time Frame: From baseline up to 6 weeks follow-up
This score is based on seven questions (overall pain,pain frequency,pain in the back,pain in the leg,numbness,weakness,and balanced disturbance.The first 6 categories are scored 1 to 5 (none,mild,moderate, severe,very severe). Balance disturbance is scored in a 1-3-5 scale (None,sometimes,often).The symptom severity scale score is the unweighted mean of all answered items (missing scores are discarded) in the questionnaire. Scoring range= 1-5.The change is calculated as the scores at the later timepoint minus the earlier timepoint expressed in terms of percentage.
From baseline up to 6 weeks follow-up
The Proportion of Patients Experiencing a Procedure or Device Related Serious Adverse Events During the First 7 Days Starting at the Surgical Procedure
Time Frame: Starting at the surgical procedure till 7 days post-operatively

Adverse events were to be summarized by proportion. All Adverse events occurring within the first 7 days after the surgical procedure were to be analyzed:

  • Day of the procedure until P+1 (where P refers to the day of the surgical procedure)
  • P+2 until P+7
Starting at the surgical procedure till 7 days post-operatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean Percentage Change in Symptom Severity at 12 Months Compared to Baseline, Using the Patient Completed Zurich Claudication Questionnaire for Symptom Severity
Time Frame: From baseline up to 12 months follow up

The Zurich Claudication questionnaire - Symptom Severity score is based on seven questions (overall pain,pain frequency,pain in the back,pain in the leg,numbness,weakness,and balanced disturbance.The first 6 categories are scored 1 to 5 (none,mild,moderate, severe,very severe). Balance disturbance is scored in a 1-3-5 scale (None,sometimes,often).This score is the unweighted mean of all answered items (missing scores are discarded). Scoring range= 1-5.

The change is calculated as the scores at the later timepoint minus the earlier timepoint expressed in terms of percentage.
From baseline up to 12 months follow up
Mean Percentage Change in Physical Function at 12 Months Compared to Baseline, Using the Zurich Claudication Questionnaire
Time Frame: From baseline up to 12 months

The Zurich Claudication Questionnaire - Physical Function score is the unweighted mean of six physical function questions ranging from 1 to 4. The six Physical Function questions ask about walking distance and ability to walk for pleasure, for shopping, and for getting around the house or apartment and from bathroom to bedroom. If more than one item was missing, the scale score was also to be considered as missing. The possible range of this score is 1.0 to 4.0.

The change is calculated as the scores at the later timepoint minus the earlier timepoint expressed in terms of percentage.
From baseline up to 12 months
Mean Change in Quality of Life Score at 12 Months Compared to Baseline
Time Frame: From baseline up to 12 months follow up
The quality of life scale covers five dimensions of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels (no health problems,moderate health problems,extreme health problems). The distribution of the response of the patients in these five dimensions was to be studied.This descriptive system was converted into a weighted health state index with Min-max score = 0-100 and 100 as most optimal score. If one or more questions are left unanswered, the questionnaire is not scored.
From baseline up to 12 months follow up
Proportion of Patients Having Procedure and/or Device Related Events During the Complete 12 Month Follow-up Period.
Time Frame: From baseline up to 12 months follow up
From baseline up to 12 months follow up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Medtronic Spinal and Biologics

Investigators

  • Study Director: E. Wuelfert, Pharm., Medtronic Spinal & Biologics

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2006

Primary Completion (ACTUAL)

May 1, 2009

Study Completion (ACTUAL)

March 1, 2010

Study Registration Dates

First Submitted

April 23, 2009

First Submitted That Met QC Criteria

April 23, 2009

First Posted (ESTIMATE)

April 24, 2009

Study Record Updates

Last Update Posted (ESTIMATE)

January 28, 2016

Last Update Submitted That Met QC Criteria

January 26, 2016

Last Verified

January 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CIP-0001-AP

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe